A Comparison of the Effects of Commerical Drugs (Ipilimumab, Nivolumab, or Pembrolizumab) Alone or in Combination with an Experimental Immunotherapy Drug for Melanoma

What we are studying

The purpose of this study is to examine the effectiveness of immune checkpoint inhibitors (drugs called ipilimumab, nivolumab, or pembrolizumab), either given alone, or in combination with an experimental immunotherapy drug for melanoma. We want to see if the combination is better than the checkpoint inhibitor given by itself. The checkpoint inhibitors used in this study have been approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with metastatic melanoma.

Who we are studying

  • Men and Women
  • Races:
    • White
    • African American
    • Asian
    • American Indian or Alaska Native
    • Native Hawaiian or Pacific Islander
    • Other
  • All Ethnicities
  • Ages 18+

Eligibility Criteria

  • Stage IV Melanoma
  • No prior treatment with CTLA4 antibodies
  • ?4 weeks since last treatment or surgery

What is involved

  • Normal exams
  • Normal imaging
  • Ipilimumab treatment
  • Blood Collection
  • Study drug injections (if randomized to study drug)


$50 travel reimbursement for study related visits only (if randomized to the experimental drug)

Contact Information

Study Coordinator
Stacey Lewis

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.